Rapid Micro reports record Q4 revenue $11.3M (+37% YoY); 2026 guidance $37-41M; Samsung Biologics expands Growth Direct

RAPID MICRO BIOSYSTEMS, INC.

Q4 total revenue $11.3M (+37% YoY); product revenue $9.3M (+78%).
FY 2025 revenue $33.6M (+20% YoY); net loss $47.1M ($1.05/share).
FY 2026 guidance: revenue $37-41M, 30-38 system placements, gross margin ~20%.
Samsung Biologics placed multi-system Growth Direct order in Q1 2026, following Amgen's Q4 2025 multi-system order.
Cash position $39M; $25M unused under Trinity Capital debt facility.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RAPID MICRO BIOSYSTEMS, INC. reported full year 2025 results: revenue $33.6 million, net income $47.1 million, EPS $1.05.

Period: full year 2025
Revenue: $33.6 million
Net income: $47.1 million
EPS: $1.05
Result: reported results

Exact text from the filing

Total revenue for the full year was $33.6 million in 2025, compared to $28.1 million in 2024, representing an increase of 20%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RAPID MICRO BIOSYSTEMS, INC. reported fourth quarter of 2025 results: revenue $11.3 million, net income $12.5 million, EPS $0.28.

Period: fourth quarter of 2025
Revenue: $11.3 million
Net income: $12.5 million
EPS: $0.28
Result: reported results

Exact text from the filing

Total revenue for the fourth quarter of 2025 was $11.3 million, compared to $8.2 million in the fourth quarter of 2024, representing an increase of 37%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RAPID MICRO BIOSYSTEMS, INC. reported full year 2026 results: revenue $37.0 million to $41.0 million. Guidance initiated.

Period: full year 2026
Revenue: $37.0 million to $41.0 million
Guidance: initiated
Result: guidance update

Exact text from the filing

For the full year 2026, the Company expects total revenue in the range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements and gross margins of approximately 20%.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

RAPID MICRO BIOSYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001380106-26-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.